China Grants BioCurex's RECAF Patent: Largest Population Country In The World Approves Technology BioCurex Inc. (OTCBB:BOCX) is pleased to announce that a patent for its proprietary RECAF(TM) technology for cancer diagnosis has been approved and granted in the People's Republic of China. The patent covers the technologies used in the Company's Histo-RECAF(TM) and Cryo-RECAF(TM)
That is from Nov 2003.
BioCurex has already been issued patents in Australia and Russia and has patents pending in Canada and Japan and most European countries with pending approvals for diagnostic and therapeutic applications which have a much greater market share potential than already stated.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.